1Twardowski ZJ.High-dose instradialytic urokinase to restore the patency of permanent central vein hemodialysis catheters[J].Am J Kidney Dis,1998,31(5):841-847.
2Taniover B,Carlton D,Saddekni S,et al.Bactere mia associated with tunneled dialysis catheters:comparison of two treatment strategies[J].Kidney Int,2000,57(5):2151-2155.
2Vascular Access Work Group. National Kidney Foundation KDOQI clinical practice guidelines for vascular accesss. Am J Kidney Dis, 2006 ( Supple 1 ) : s248-s723.
3John C, Martin C, Gerard F, et al. Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimierobial lock therapy for Staphylococcus epidermidis cen- tral venous catheter-related biofilm infections,Antimicrob. A- gents Chemother, 2003,47: 3145-3148.
4No authors Listed Xause of death. USRDS United States Renal Data System. AM J Kidney Dis, 1997,30(2 supol 1 ) : 107-117.
5Chen CY, Liu CC, Sun WZ. Evidence-based review on catheter related thrombosis of the implantable venous accessdevice. Tzu Chi Medicaljoumal, 2007,19 : 207-219.
6Quarello F,Forneris G, Borca M, et al. Do deep venous cathe- ters have advantages over arteriovenous fistulas or grafts. J Nephrol, 2006,19: 265-279.
